Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study.
Diagnostics
Medullary thyroid carcinoma
Outcome
Pathology
Surgery
Trends
Journal
European thyroid journal
ISSN: 2235-0640
Titre abrégé: Eur Thyroid J
Pays: England
ID NLM: 101604579
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
07
06
2018
revised:
21
09
2018
entrez:
26
2
2019
pubmed:
26
2
2019
medline:
26
2
2019
Statut:
ppublish
Résumé
Medullary thyroid carcinoma (MTC) is rare. Nationwide population-based studies are important to evaluate its clinical course. To describe all patients with MTC in Norway during 1994-2016 and compare time-related trends in diagnostics and surgical treatment, including prognostic factors for biochemical cure and disease-specific survival (DSS). This retrospective population-based cohort study includes data for 228 out of 237 patients (96%) with MTC; 201 patients were surgically treated. Patients were identified in the 4 regional centers treating MTC and by the Cancer Registry of Norway. Data were collected from patients' files. Trends were compared over 2 study periods. MTC accounted for 4.2% of thyroid carcinomas. During the study periods, the incidence increased from 0.18 to 0.25: 100,000 per year, preoperative diagnostics improved with increased use of calcitonin, ultrasound, and fine-needle cytology ( Preoperative diagnostics have improved over time with increased therapeutic control. A low ratio of metastatic and dissected lymph nodes predicts better outcomes in patients with metastatic lymph nodes.
Sections du résumé
BACKGROUND
BACKGROUND
Medullary thyroid carcinoma (MTC) is rare. Nationwide population-based studies are important to evaluate its clinical course.
OBJECTIVES
OBJECTIVE
To describe all patients with MTC in Norway during 1994-2016 and compare time-related trends in diagnostics and surgical treatment, including prognostic factors for biochemical cure and disease-specific survival (DSS).
METHODS
METHODS
This retrospective population-based cohort study includes data for 228 out of 237 patients (96%) with MTC; 201 patients were surgically treated. Patients were identified in the 4 regional centers treating MTC and by the Cancer Registry of Norway. Data were collected from patients' files. Trends were compared over 2 study periods.
RESULTS
RESULTS
MTC accounted for 4.2% of thyroid carcinomas. During the study periods, the incidence increased from 0.18 to 0.25: 100,000 per year, preoperative diagnostics improved with increased use of calcitonin, ultrasound, and fine-needle cytology (
CONCLUSIONS
CONCLUSIONS
Preoperative diagnostics have improved over time with increased therapeutic control. A low ratio of metastatic and dissected lymph nodes predicts better outcomes in patients with metastatic lymph nodes.
Identifiants
pubmed: 30800639
doi: 10.1159/000493977
pii: etj-0008-0031
pmc: PMC6381913
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31-40Références
Cancer. 2000 Mar 1;88(5):1139-48
pubmed: 10699905
J Clin Endocrinol Metab. 2004 Jan;89(1):163-8
pubmed: 14715844
Lancet Oncol. 2006 Feb;7(2):132-40
pubmed: 16455477
Cancer. 2006 Nov 1;107(9):2134-42
pubmed: 17019736
J Clin Endocrinol Metab. 2007 Feb;92(2):450-5
pubmed: 17119000
Clin Endocrinol (Oxf). 2006 Dec;65(6):729-36
pubmed: 17121523
Eur J Surg Oncol. 2007 May;33(4):493-7
pubmed: 17125960
J Clin Endocrinol Metab. 2008 Jun;93(6):2173-80
pubmed: 18364376
Ann Surg Oncol. 2008 Sep;15(9):2493-9
pubmed: 18594930
J Clin Endocrinol Metab. 2010 Jun;95(6):2655-63
pubmed: 20339026
Clin Endocrinol (Oxf). 2011 Feb;74(2):241-7
pubmed: 21054478
Cancer. 2012 Feb 1;118(3):620-7
pubmed: 21717441
Curr Opin Oncol. 2013 Jan;25(1):20-6
pubmed: 23079930
APMIS. 1990 Jun;98(6):549-58
pubmed: 2383397
Ann Surg. 2014 Apr;259(4):800-6
pubmed: 23979292
Eur J Surg Oncol. 2015 Jun;41(6):766-72
pubmed: 25468749
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Eur J Endocrinol. 2016 Sep;175(3):219-28
pubmed: 27334331
Thyroid. 2016 Sep;26(9):1225-38
pubmed: 27400880
Oncotarget. 2016 Oct 4;7(40):65937-65945
pubmed: 27588396
Surgery. 2017 Jan;161(1):137-146
pubmed: 27842913
World J Surg. 2018 Feb;42(2):367-375
pubmed: 29134313
Thyroid. 2018 Mar;28(3):369-376
pubmed: 29402183
Surgery. 1986 Jan;99(1):60-6
pubmed: 3942001
Hum Mol Genet. 1994 Feb;3(2):237-41
pubmed: 7911697
Surg Today. 1994;24(2):112-21
pubmed: 8054788
Nature. 1993 Jun 3;363(6428):458-60
pubmed: 8099202
Hum Mol Genet. 1993 Jul;2(7):851-6
pubmed: 8103403
Surgery. 1993 Dec;114(6):1090-5; discussion 1095-6
pubmed: 8256212
Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73
pubmed: 9578814